Mark Sirgo, PharmD
Chief Executive Officer
Dr. Mark Sirgo is Chief Executive Officer of ArunA Bio. Dr. Sirgo brings over 35 years of pharmaceutical experience to ArunA Bio from drug development through global product commercialization. Most recently, Dr. Sirgo served as President and CEO of BioDelivery Sciences International (BDSI:Nasdaq), a specialty pharmaceutical company focused in CNS/pain. While leading BDSI, Dr. Sirgo was successful in raising nearly $600 million in capital through partnerships and financings to support the development, FDA approval and commercial launch of three products utilizing the company’s proprietary drug delivery technology.
Steven Stice, PhD
Co-Founder, Chief Scientific Officer
Dr. Steve Stice is Co-Founder and Chief Scientific Officer of ArunA Bio, where he directs the company’s clinical and research operations. He is also University of Georgia, DW Brooks Distinguished Professor and Director of the Regenerative Bioscience Center, and holds a Georgia Research Alliance Eminent Scholar endowed chair.
Chief Operating Officer
Tracey Worthington-Stice is the Chief Operating Officer (COO) of ArunA Bio. Under her direction, ArunA was the first to commercialize human neural stem cells derived from human pluripotent stem cells and is now prepared to model a new class of cell-free biologics, specifically exosomes, with the potential to modify outcomes CNS damage, and neural degenerative diseases.
Executive Vice President, Corporate and Commercial Development
Al Medwar is the Executive Vice President, Corporate and Commercial Development of ArunA Bio. He brings nearly 30 years of pharmaceutical experience to ArunA Bio, much of which has been with development stage companies in a number of roles including business development, sales, marketing, and investor/public relations. Prior to joining the company, Mr. Medwar was Senior Vice President, Corporate and Business Development for BioDelivery Sciences (Nasdaq: BDSI) where he spent eleven years and played an important role in building the company from an early development to a commercial stage entity.